Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455543 | 0.87 | ACHE (0.46) | ALDH1A1HPGDCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL2388924 | 0.82 | PGR (0.41) | ALDH1A1HPGDPGRABCG2CYP1A2 | |
| SCHEMBL12258747 | 0.81 | TUBB1 (0.47) | ABCG2CYP1A2TUBB4ATUBBTUBA3C | |
| SCHEMBL12258658 | 0.76 | HPGD (0.40) | ALDH1A1HPGDCYP1A2 | |
| SCHEMBL2456957 | 0.76 | CYP1A2 (0.46) | ALDH1A1ABCG2CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL6093598 | 0.73 | ERN1 (0.53) | ALDH1A1HPGDABCG2CYP1A2CYP1A1 | |
| SCHEMBL9958096 | 0.71 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL9957932 | 0.71 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL2083820 | 0.71 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL9957685 | 0.71 | CA12 (0.54) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150133675-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885PGR 3549/4885 |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885PGR 3549/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885PGR 3549/4885 |
| US-20150133675-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885PGR 3549/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885PGR 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.